What's new

EMEA-003389-PIP01-23

EMEA-003389-PIP01-23

Mar 17, 2025 - 16:38
 0
EMEA-003389-PIP01-23
EMEA-003389-PIP01-23
Read More

Tags:

Previous Article

Curevo rounds up $110M to challenge GSK’s Shringrix, nabs Moncef Slaoui to lead ...

Next Article

The D Brief: Strikes in Yemen; Border destroyer; DOGE vs. nuclear-security agenc...

Related Posts

Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 13, 2025  0

Orphan designation: Magrolimab Treatment of myelodysplastic syndromes, 26/06/2020 Withdrawn

Orphan designation: Magrolimab Treatment of myelodyspla...

Mar 12, 2025  0

Human medicines European public assessment report (EPAR): Xaluprine (previously Mercaptopurine Nova Laboratories), mercaptopurine, Date of authorisation: 09/03/2012, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 13, 2025  0